Literature DB >> 25756770

Response to Parikh.

David J Miklowitz1, Christopher D Schneck, Boris Birmaher, Melissa P Delbello, David A Axelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25756770      PMCID： PMC4629918          DOI： 10.1176/appi.ajp.2014.14070887r

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  4 in total

1.  Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program.

Authors:  David J Miklowitz; Michael W Otto; Ellen Frank; Noreen A Reilly-Harrington; Stephen R Wisniewski; Jane N Kogan; Andrew A Nierenberg; Joseph R Calabrese; Lauren B Marangell; Laszlo Gyulai; Mako Araga; Jodi M Gonzalez; Edwin R Shirley; Michael E Thase; Gary S Sachs
Journal:  Arch Gen Psychiatry       Date:  2007-04

2.  Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program.

Authors:  S M Sotsky; D R Glass; M T Shea; P A Pilkonis; J F Collins; I Elkin; J T Watkins; S D Imber; W R Leber; J Moyer
Journal:  Am J Psychiatry       Date:  1991-08       Impact factor: 18.112

Review 3.  Treatment of bipolar disorder.

Authors:  John R Geddes; David J Miklowitz
Journal:  Lancet       Date:  2013-05-11       Impact factor: 79.321

4.  A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME].

Authors:  Sagar V Parikh; Ari Zaretsky; Serge Beaulieu; Lakshmi N Yatham; L Trevor Young; Irene Patelis-Siotis; Glenda M Macqueen; Anthony Levitt; Tamara Arenovich; Pablo Cervantes; Vytas Velyvis; Sidney H Kennedy; David L Streiner
Journal:  J Clin Psychiatry       Date:  2012-06       Impact factor: 4.384
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.